EVALUATION OF THE EFFICACY OF EXOGENOUS MELATONIN IN THE COMBINATION THERAPY OF PREMENSTRUAL DISORDERS

DOI: https://doi.org/10.29296/25877305-2019-03-05
Download full text PDF
Issue: 
3
Year: 
2019

Professor O. Gizinger(1), Biol. Dr.; O. Romanenko(2), Candidate of Medical Sciences 1-South Ural State Medical University, Chelyabinsk 2-Reproductive Health Medical Center, Chelyabinsk

The paper analyzes the effects of Melaxen® (Unipharm) at a dose of 1.5 mg taken orally once daily 30–40 minutes before bedtime for one month on the severity of manifestations of premenstrual symptoms and sleep disorders. It is shown that Melaxen® can be recommended to treat and correct premenstrual disorders.
Keywords: 
gynecology
melatonin
sleep disorders
menstrual cycle
premenstrual syndrome

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Burchakov D.I. Melatonin-adaptogen zhenskoj reproduktivnoj sistemy // Effektivnaja farmakoterapija. – 2015; 5: 14–8 [Burchakov D.I. Melatonin – an Adaptogen for Female Reproductive System // Effektivnaya farmakoterapiya. – 2015; 5: 14–8 (in Russ.)].
  2. Gafarova E.A Klinicheskoe znachenie melatonina v razvitii simptomov patologicheskogo klimaksa. Avtoref. ... dis. kand. med. nauk. Kazan', 2005 [Gafarova E.A Klinicheskoe znachenie melatonina v razvitii simptomov patologicheskogo klimaksa. Avtoref. ... dis. kand. med. nauk. Kazan’, 2005 (in Russ.)].
  3. Gizinger O.A., Osikov M.V., Ogneva O.I. Rol' melatonina v ustranenii immunnyh narushenij pri eksperimental'nom desinhronoze // Vrach. – 2014; 12: 73–6 [Gizinger O.A., Oslkov M.V., Ogneva O.I. Role of melatonin in correcting immune disorders in experimental desynchronosis under led lighting // Vrach. – 2014; 12: 73–6 (in Russ.)].
  4. Mihajlov, B.V. Problema depressij v obschesomaticheskoj praktike // Mezhdunarodnyj meditsinskij zhurnal. – 2003; 34 (4): 22–7 [Mikhailov, B.V. Problema depressii v obshchesomaticheskoi praktike // Mezhdunarodnyi meditsinskii zhurnal. – 2003; 34 (4): 22–7 (in Russ.)]
  5. Mal'tseva L.I., Gafarova E.A. Rol' melatonina v razvitii klimaktericheskogo sindroma u zhenschin i vozmozhnosti primenenija melatonina v lechenii simptomov patologicheskogo klimaksa // RMZh. – 2007; 15 (4): 266–9 [Mal’tseva L.I., Gafarova E.A. Rol’ melatonina v razvitii klimaktericheskogo sindroma u zhenshchin i vozmozhnosti primeneniya melatonina v lechenii simptomov patologicheskogo klimaksa // RMZh. – 2007; 15 (4): 266–9 (in Russ.)].
  6. Mezhevetinova E.A., Prilepskaja V.N. Predmenstrual'nyj sindrom // Ginekologija. – 2005; 4: 23–6 [Mezhevetinova E.A., Prilepskaya V.N. Predmenstrual’nyi sindrom // Ginekologiya. – 2005; 4: 23–6 (in Russ.)]
  7. Osikov M.V., Gizinger O.A., Ogneva O.I. Immunotropnye effekty melatonina pri eksperimental'nom desinhronoze // Rossijskij immunologicheskij zhurnal. – 2014; 8 (2–1): 119–22 [Osikov M.V., Gizinger O.A., Ogneva O.I. Immunotropnye effekty melatonina pri eksperimental’nom desinkhronoze // Rossiiskii immunologicheskii zhurnal. – 2014; 8 (2–1): 119–22 (in Russ.)].
  8. Osikov M.V., Gizinger O.A., Ogneva O.I. Immunnyj status i povedencheskaja aktivnost' pri eksperimental'nom desinhronoze v uslovijah ljuminestsentnogo osveschenija // Rossijskij immunologicheskij zhurnal. – 2015; 9 (2–1): 301–3 [Osikov M.V., Gizinger O.A., Ogneva O.I. Immune status and behavioral activity in experimental desynchronoses under fluorescent lighting conditions // Rossiiskii immunologicheskii zhurnal. – 2015; 9 (2–1): 301–3 (in Russ.)].
  9. Osikov M.V., Gizinger O.A., Ogneva O.I. Mehanizm vlijanija melatonina na immunnyj status pri eksperimental'nom desinhronoze v uslovijah svetodiodnogo osveschenija // Meditsinskaja immunologija. – 2015; 17 (6): 517–24 [Osikov M.V., Gizinger O.A., Ogneva O.I. Mechanisms of melatonin effects upon immune state in experimental desynchronoses produced under the LED illumination conditions // Medical Immunology (Russia)/Meditsinskaya Immunologiya. – 2015; 17 (6): 517–24 (in Russ.)]. DOI: 10.15789/1563-0625-2015-6-517-524
  10. Chertok N., Mamylina N., Gizinger O. i dr. Reoentsefalograficheskie pokazateli v postimmobilizatsionnom periode u zhenschin v postmenopauze s perelomom luchevoj kosti // Vrach. – 2016; 4: 63–8 [Rheoencephalographic indices in the post-immobilization period in postmenopausal women with a fracture of the radius // Vrach. – 2016; 4: 63–8 (in Russ.)].
  11. Chistjakova O.O. Melatonin v terapii klimaktericheskih i psihicheskih rasstrojstv // Kazanskij meditsinskij zhurnal. – 2005; 86 (1): 31–4 [Chistyakova O.O. Melatonin in treatment of climacteric and psychic disorders // Kazanskii meditsinskii zhurnal. – 2005; 86 (1): 31–4 (in Russ.)].
  12. Jahno N.N. Otchet o klinicheskoj effektivnosti preparata «MELAKSEN» firmy Unipharm-USA (SShA) pri lechenii insomnij // Lechaschij vrach. – 1999; 10: 34–7 [Yakhno N.N. Otchet o klinicheskoi effektivnosti preparata «MELAKSEN» firmy Unipharm-USA (SShA) pri lechenii insomnii // Lechashchii vrach. – 1999; 10: 34–7 (in Russ.)].
  13. Boutin J., Audinot V., Ferry G. et al. Molecular tools to study melatonin pathways and actions // Trends Pharmacol. Sci. – 2005; 26 (8): 412–9.
  14. Cutando A., López-Valverde A., Arias-Santiago S. et al. Role of melatonin in cancer treatment // Anticancer Res. – 2012; 32 (7): 2747–53.
  15. Di Bella G., Mascia F., Gualano L. et al. Melatonin Anticancer Effects: Review // Int. J. Mol. Sci. – 2013; 14 (2): 2410–30.
  16. Dong C., Yuan L., Dai J. et al. Melatonin inhibits mitogenic cross-talk between retinoic acid-related orphan receptor alpha (RORalpha) and ERalpha in MCF-7 human breast cancer cells // Steroids. – 2010; 75 (12): 944–51.
  17. Dubocovich M., Rivera-Bermudez M., Gerdin M. et al. Molecular pharmacology, regulation and function of mammalian melatonin receptors // Front. Biosci. – 2003; 8: 1093–108.
  18. Espino J., Pariente J., Rodriguez A. Oxidative Stress and Immunosenescence: Therapeutic Effects of Melatonin [Electronic resource] // Oxid Med. Cell Longev. – 2012; Mode of access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549369/pdf/OXIMED2012-670294.pdf (Date of access: 06.01.2019).
  19. Galano A., Tan D., Reiter R. Melatonin as a natural ally against oxidative stress: a physicochemical examination // J. Pineal. Res. – 2011; 51 (1): 1–16.
  20. Garcia-Mauriño S., Pozo D., Carrillo-Vico A. et al. Melatonin activates Th1 lymphocytes by increasing IL-12 production // Life Sci. – 1999; 65 (20): 2143–50.
  21. Korkmaz A., Reiter R., Topal T. et al. Melatonin: An Established Antioxidant Worthy of Use in Clinical Trials // Mol. Med. – 2009; 15 (1–2): 43–50.
  22. Lerner A., Case J., Takahashi Y. Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands // J. Biol. Chem. – 1960; 235: 1992–7.
  23. Luchetti F., Betti M., Canonico B. et al. ERK MAPK activation mediates the antiapoptotic signaling of melatonin in UVB-stressed U937 cells // Free Radic. Biol. Med. – 2009; 46 (3): 339–51.
  24. Pandi-Perumal S., Trakht I., Srinivasan V. et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways // Prog. Neurobiol. – 2008; 85 (3): 335–53.
  25. Paradies G., Petrosillo G., Paradies V. et al. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease // J. Pineal Res. – 2010; 48 (4): 297–310.
  26. Pawlikowski M., Kolomecka M., Wojtczak A. et al. Effects of six months melatonin treatment on sleep quality and serum concentrations of estradiol, cortisol, dehydroepiandrosterone sulfate, and somatomedin C in elderly women // Neuro Endocrinol. Lett. – 2002; 23 (1): 17–9.
  27. Roca A., Godson C., Weaver D. et al. Structure, characterization, and expression of the gene encoding the mouse Mel1a melatonin receptor // Endocrinology. – 1996; 137 (8): 3469–77.
  28. Reppert S., Godson C., Mahle C.D. et al. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor // Proc. Natl. Acad. Sci. USA. – 1995; 92 (19): 8734–8.
  29. Sudnikovich E., Maksimchik Y., Zabrodskaya S. et al. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats // Eur. J. Pharmacol. – 2007; 569 (3): 180–7.
  30. Schmidt P., Nieman L., Grover G. et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome // N. Engl. J. Med. – 1991; 324: 1174–9.
  31. Toffol E., Kalleinen N., Haukka J. et al. The effect of hormone therapy on serum melatonin concentrations in premenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study // Maturitas. – 2014; 77 (4): 361–369.
  32. Peshikova M.V., Zhukovskaja E.V., Dolgushin I.I. Imunologicheskij distress pri tjazhelyh infektsijah u detej // Onkogematologija. – 2008; 3 (4): 64 [Peshikova M.V., Zhukovskaya E.V., Dolgushin I.I. Immunological distress in severe infections in children // Oncohematology. – 2008; 3 (4): 64 (in Russ.)]